DGAP-News
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016 interim communication
DGAP-News: 4SC AG / Key word(s): Quarterly / Interim Statement/Quarter
Results
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016
interim communication
06.05.2016 / 09:38
The issuer is solely responsible for the content of this announcement.
Results
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016
interim communication
06.05.2016 / 09:38
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016
interim communication
Planegg-Martinsried, Germany, 6 May 2016 - 4SC AG (4SC, FSE Prime Standard:
VSC) will publish its Q1 2016 interim communication on 12 May 2016. On this
day, the Management Board of 4SC AG will host a conference call at 4 pm
CEDT (10 am EDT) to inform about important developments in the reporting
period and beyond.
Investors, financial analysts, and journalists interested in participating
in the conference call can access via the following telephone numbers:
Date: 12 May 2016
Time: 4 pm CEDT (10 am EDT)
Dial-in numbers: +49 89 1214 00699 (Germany)
+44 20 3427 1912 (UK)
+1 212 444 0412 (USA)
+49 89 1214 00699 (all other countries)
Conference ID: 3705834
A presentation document supporting the conference call will be available on
12 May 2016, on the webpage www.4sc.com in section "Investors & Media" /
"Events & Presentations" / "Conference Calls & Webcasts". After the event,
a replay can be accessed from there as well.
- Press release ends -
Further information
About 4SC
4SC (www.4cs.com) is a biotechnology company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options for cancer
patients that are more tolerable and efficacious than existing therapies,
provide a better quality of life and offer increased life expectancy. The
Company's pipeline comprises promising products that are in various stages
of clinical development. 4SC's aim is to generate future growth and enhance
its enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 67 employees at 31 December
2015. 4SC has been listed on the Prime Standard of the Frankfurt Stock
Exchange since December 2005.
Forward-looking information
This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.
More information about 4SC
4SC AG
Corporate Communications & Investor Relations
Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73
Dr. Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66
MC Services
Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40
---------------------------------------------------------------------------
06.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Planegg-Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
461115 06.05.2016
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016
interim communication
Planegg-Martinsried, Germany, 6 May 2016 - 4SC AG (4SC, FSE Prime Standard:
VSC) will publish its Q1 2016 interim communication on 12 May 2016. On this
day, the Management Board of 4SC AG will host a conference call at 4 pm
CEDT (10 am EDT) to inform about important developments in the reporting
period and beyond.
Investors, financial analysts, and journalists interested in participating
in the conference call can access via the following telephone numbers:
Date: 12 May 2016
Time: 4 pm CEDT (10 am EDT)
Dial-in numbers: +49 89 1214 00699 (Germany)
+44 20 3427 1912 (UK)
+1 212 444 0412 (USA)
+49 89 1214 00699 (all other countries)
Conference ID: 3705834
A presentation document supporting the conference call will be available on
12 May 2016, on the webpage www.4sc.com in section "Investors & Media" /
"Events & Presentations" / "Conference Calls & Webcasts". After the event,
a replay can be accessed from there as well.
- Press release ends -
Further information
About 4SC
4SC (www.4cs.com) is a biotechnology company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options for cancer
patients that are more tolerable and efficacious than existing therapies,
provide a better quality of life and offer increased life expectancy. The
Company's pipeline comprises promising products that are in various stages
of clinical development. 4SC's aim is to generate future growth and enhance
its enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 67 employees at 31 December
2015. 4SC has been listed on the Prime Standard of the Frankfurt Stock
Exchange since December 2005.
Forward-looking information
This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.
More information about 4SC
4SC AG
Corporate Communications & Investor Relations
Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73
Dr. Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66
MC Services
Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40
---------------------------------------------------------------------------
06.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Planegg-Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
461115 06.05.2016
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte